What Alimemazine Treats: Main Uses and Benefits

Alimemazine is commonly used across domains where additional symptomatic support is needed, primarily to manage severe and intractable itching (pruritus) associated with various dermatological and allergic conditions, most notably urticaria (hives). The medication is considered relevant for the management of urticaria and pruritus, with sedative properties, applicable within clinical settings that involve acute or disruptive symptom patterns. It is relevant for easing antipruritic symptoms in patients experiencing intense cutaneous discomfort.

Its therapeutic application extends to addressing symptoms of psychological tension, anxiety, and hyperarousal often present in conditions like neuroses, and may assist with managing disturbed sleep patterns, particularly transient insomnia linked to discomfort or tension. The calming effect supports patients during episodes of heightened discomfort. The medication’s sedative properties may assist with rest and support more stable sleep patterns, contributing to easing the overall symptom load.

Quick Fact: Relief for Combined Pruritus and Anxiety

---

Alleviation of Anxiety and Hyperarousal

The medication is applied to address symptoms of psychological tension, anxiety, and hyperarousal often present in conditions like neuroses, which may assist with a calming effect. It offers supportive therapeutic benefit by helping to reduce nervousness and the overall emotional burden of distressing manifestations in symptomatic episodes.

Stabilization of Sleep Patterns Disturbed by Discomfort

The medication is commonly used to help with disturbed sleep patterns, particularly transient insomnia that is secondary to underlying physical discomfort, such as severe itching, or significant emotional tension. The medication's sedative properties may assist with rest and support more stable sleep patterns, contributing to easing the impact of symptoms on recovery and general well-being.

Who Can and Cannot Use Alimemazine?

The decision to use Alimemazine is strictly governed by medical eligibility criteria and specific contraindications outlined in official regulatory documents (such as those from the EMA). This medicine is not approved for use in the United States by the FDA.

---

Contraindicated Populations (Must Not Use)

Use of Alimemazine is strictly contraindicated (prohibited) for individuals with the following conditions or characteristics:

• Hypersensitivity (allergy) to alimemazine, other phenothiazines, or any component of the formulation.
• Children less than two years of age (due to risk of severe sedation and respiratory depression).
• Severe hepatic (liver) or renal (kidney) dysfunction.
• Epilepsy or a history of seizures, Parkinson's disease, narrow-angle glaucoma.
• Disorders like myasthenia gravis, prostatic hypertrophy (enlarged prostate), or a history of agranulocytosis.

---

Restricted or Cautionary Use

Certain populations may use Alimemazine only with special consideration and under strict medical supervision:

• Elderly patients are at an increased risk of side effects like orthostatic hypotension, sedation, falls, and urinary retention, and require careful monitoring.
• Pregnant or breast-feeding patients should avoid the medicine unless deemed essential by a physician, and breast-feeding must be suspended during treatment. Use with alcohol is also strictly prohibited.

Alimemazine, a phenothiazine derivative, carries a significant risk for several pharmacodynamic interactions that can intensify central nervous system (CNS) and cardiac effects. The most notable interaction is the additive increase in CNS depression when co-administered with other CNS depressants. This drug class includes sedating antidepressants (e.g., amitriptyline), barbiturates, benzodiazepines, hypnotics (e.g., zolpidem, zopiclone), opioid analgesics, and alcohol. Concurrent use of these substances may result in enhanced drowsiness, sedation, and psychomotor impairment.

Another major consideration is the risk of QTc interval prolongation, which may lead to serious cardiac arrhythmias. Caution is advised when Alimemazine is combined with any medicinal product known to prolong the QTc interval, such as certain antiarrhythmics, antipsychotics, and antidepressants. This combined effect increases the risk of ventricular arrythmias like Torsades de Pointes. The drug’s anticholinergic properties also mean that use with other anticholinergic agents (e.g., specific antiparkinson drugs, antispasmodics) can lead to additive effects like dry mouth, urinary retention, and constipation. Furthermore, Alimemazine may lower the convulsive threshold, warranting vigilance when co-administered with other medicines that also possess this property. Finally, its hypotensive effects can be amplified by other blood pressure-lowering drugs.

Alimemazine, a first-generation phenothiazine derivative, functions primarily as an inverse agonist at the histamine H1 receptor (H1R). This interaction blocks the binding of endogenous histamine and also suppresses the receptor's intrinsic constitutive activity, thereby decreasing H1R-mediated signaling in both central and peripheral tissues.

The drug exhibits additional antagonism at other molecular targets, including the muscarinic acetylcholine receptors and, to a lesser extent, serotonin receptors. The antagonism of H1R is coupled to a Gq protein pathway, inhibiting the activation of phospholipase C, which in turn reduces the formation of inositol trisphosphate (IP3) and diacylglycerol (DAG). This intracellular cascade ultimately results in a reduced mobilization of intracellular calcium ions (Ca^2+).

At the system level, central nervous system penetration allows the drug to modulate neurotransmission in the brain. Peripherally, the suppression of histamine and Ca^2+ signaling leads to decreased capillary permeability and reduced vasodilation, while also stabilizing mast cell membranes to limit further release of histamine and pro-inflammatory mediators. The overall physiological consequence is a widespread dampening of H1R-mediated and cholinergic signaling.

How to Use Alimemazine: Official Administration Guidelines

Alimemazine is administered orally only, available as film-coated tablets or an oral solution (syrup). Use must adhere strictly to the dosing schedules and specific administration requirements outlined in official product information.

---

Official Dosage and Frequency

Population Group	Indication	Standard Regimen (Do not exceed)
Adults	Urticaria and Pruritus	10 mg two or three times daily.
Older Adults	Urticaria and Pruritus	Dose must be reduced: 10 mg once or twice daily.
Children 2–12 Years	Urticaria and Pruritus	2.5 mg to 5 mg three or four times daily (based on age).
Children 2–7 Years	Sedative before Anaesthesia	Maximum dose of 2 mg per kg bodyweight, given as a single dose.

In cases classified as intractable, the daily adult dose may be increased up to a maximum of 100 mg in divided doses. Use is not recommended for children under two years of age.

---

Administration Requirements

1. Route and Form Selection: The medicine is taken exclusively by mouth. For paediatric use, the oral solution is the recommended form. For pre-anaesthesia sedation, the higher concentration syrup (e.g., 30 mg/5 ml) should be used to limit excipient exposure.
2. Dosing Accuracy: When using the oral solution, a graduated syringe or pipette provided in the pack must be used for accurate volume measurement. Prescribing documentation advises that the dose may be taken after meals.
3. Timing: For general use (pruritus), the dose is divided throughout the day. For sedation, the single dose must be administered precisely 1–2 hours before the operation. The lowest effective dose should be used for the shortest possible treatment time.

Research Evidence / Overview of Studies for Alimemazine

Evidence for Use in Managing Severe Itching (Pruritus) and Hives (Urticaria)

Research exploring Alimemazine for conditions that may involve severe itching has generally been applied in studies examining patient-reported experiences. The existing evidence base largely involves older, small-scale Randomized Controlled Trials (RCTs) and systematic reviews that often group Alimemazine with other medications of its class. These studies typically included adult patients with conditions, such as chronic hives (urticaria). The outcomes that research examined were primarily patient-reported assessments of itch severity and measurements related to the evolution of symptoms, such as changes in visible signs of skin irritation. The observation periods in focused trials were typically short-term, lasting days or up to a few weeks.

Studies report how symptoms evolved in the observed populations, showing patterns in the short-term changes measured during the study period. Some trials described measurements related to the frequency or visibility of wheals associated with urticaria. Findings were mixed, and evidence for treating forms of itching not related to hives, such as that linked to atopic dermatitis, remains limited and heterogeneous across different scientific publications.

Evidence for Use in Disturbed Sleep Patterns and Sedation

Alimemazine was studied for conditions involving periods of heightened symptoms, such as sleep disturbances. Research exploring short-term symptom changes includes small-scale RCTs, often employing cross-over designs, and systematic reviews focused on sedative antihistamines. Studies explored outcomes reflecting daily functioning or activity level, such as the time required to fall asleep and the frequency of night awakenings. These investigations typically monitored responses over defined time intervals and included children, adolescents, and adults experiencing temporary sleep interruption.

Trials reported measurements related to sleep outcomes, which were observed in the studied populations. Studies reported how symptoms evolved in the observed populations, describing patterns that showed changes in subjective sleep parameters. Findings from available RCTs regarding outcomes in complex or chronic sleep disorders were often inconsistent.

Long-Term Studies and Key Gaps in the Research

Across all indications, research exploring short-term symptom changes is most common, but data for long-term outcomes remain insufficient. Follow-up durations were typically limited to days or a few weeks in the studies that were conducted. The main areas of uncertainty include the need for updated, large-scale, placebo-controlled trials for both itching and sleep indications. Furthermore, the research involves studies with diverse methodologies; many foundational reports are older, and comparative evidence is limited. Specifically, the long-term effects are not fully established, and data for certain specific populations remain insufficient.

Key Studies & References

1. A systematic review of treatments for settling problems and night waking in young children
2. Evidence review for Prescribing Clinical Network Medicine details (Alimemazine for urticaria/pruritus)

Common questions about Alimemazine (FAQ)

Q: Is Alimemazine a type of antihistamine?

A: Yes, Alimemazine is officially classified by regulatory bodies as a first-generation H1-antihistamine. It belongs to the phenothiazine derivative chemical class, which is similar to certain older antipsychotic medications. This classification is based on its primary function of blocking the action of histamine in the body.

Q: Is it safe to drive after taking Alimemazine?

A: Official product information contains a specific warning that patients must be aware of its potential to cause drowsiness. Because of this effect, regulatory documents advise individuals not to drive or operate heavy machinery, particularly during the early stages of treatment.

Q: What is the maximum daily dose for an adult with intractable pruritus?

A: Official prescribing information indicates the maximum dose for adults with intractable pruritus is higher than the standard regimen. However, specific dosing schedules must always be determined by a healthcare provider based on the individual's condition and regulatory guidelines.

Q: Can I take Alimemazine on an empty stomach?

A: Official administration guidelines advise that a dose of Alimemazine may be taken after meals. Taking the medicine with food is generally mentioned to help reduce the incidence of side effects. Official information does not prohibit taking it on an empty stomach.

Q: What should I do if I suspect an overdose of Alimemazine?

A: Regulatory documents describe the signs of an overdose, which can include serious effects like Neuroleptic Malignant Syndrome, severe cardiac arrhythmias, and central nervous system (CNS) depression. Due to the potential for serious effects, official information indicates the need for immediate emergency medical attention if an overdose is suspected.

Q: How long does Alimemazine take to start working for itching?

A: A specific, official onset of action time for relieving itching (antipruritic effect) is not explicitly listed in regulatory text. However, clinical data related to the drug's absorption suggests that its peak concentration in the body is generally reached about 1 to 2 hours after taking it by mouth.

Q: What are the withdrawal symptoms of Alimemazine?

A: Official product information does not explicitly list 'withdrawal symptoms.' The effects of suddenly stopping treatment are not typically detailed in the product label.

Q: Can Alimemazine be crushed or chewed?

A: The tablets are supplied as film-coated products. Alterations to the tablet form, such as crushing or chewing, are not typically addressed in the product label. The oral solution is a recommended alternative for individuals with difficulty swallowing.

Q: What is the longest I can safely take Alimemazine for sleep?

A: Regulatory evidence focuses primarily on the drug's use in short-term symptom management. The research cited in product information primarily involves short observation periods, but there is no specific, universally defined regulatory maximum duration stated for its use as a sleep aid.

Q: What is the full chemical name and formula for Alimemazine?

A: The active ingredient is most commonly used as the tartrate salt, which is referred to as Alimemazine tartrate. This common name is consistent with international nonproprietary nomenclature (INN).

Storage Conditions

Formulation	Required Storage Condition	Post-Opening Stability
Film-Coated Tablets	Store below 30 C in the original package to protect from light.	No specific in-use limit stated.
Oral Solution	No special storage conditions for the unopened product.	Use within 30 days after first opening.

All Alimemazine products must be kept out of the sight and reach of children as a mandatory safety measure. The product must not be disposed of with household garbage or poured into the wastewater system. Unused or expired medication must be discarded according to local regulations for pharmaceutical waste.